Notable healthcare headlines for the week: J&J, GSK, Merck, and Cassava Sciences in focus
U.S. stock indices slump amid tariff talks while healthcare sees major developments: J&J faces a $1.6B lawsuit, new FDA approvals, and a $2B ...
23andMe’s rise and fall, in four charts
Genetic testing service 23andMe has filed for Chapter 11 bankruptcy protection to keep the company running while reorganizing ...
Thrivent Financial for Lutherans Sells 3,484 Shares of GSK plc (NYSE:GSK)
Thrivent Financial for Lutherans lowered its position in shares of GSK plc (NYSE:GSK – Free Report) by 6.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 49,864 shares of the ...
pharmaphorum22h
GSK poaches Pfizer exec Dormitzer as new vaccines R&D chief
GlaxoSmithKline has found a replacement for head of vaccines R&D Emmanuel Hanon, who left the company for a US biotech earlier this year, hiring Phil Dormitzer from Pfizer.
pharmaphorum22h
GSK goes all-in on CureVac’s mRNA vaccines
GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...